| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 21 oct 2026Próximo | Q3 2026 | — | 5,85 | 2,19 B |
28 ago 2026
Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers. These approvals broaden options for HER2 testing in cancer care and support more tailored treatment...
24 ago 2026
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline.4 Developed in collaboration with Eli Lilly and Company, Elecsys pTau217
23 ago 2026
Roper's Q2 8.5% revenue growth and a 233% EPS increase were driven by equity gains from Indicor and robust segment performance. Read why ROP stock is a Buy.
22 ago 2026
Genentech’s plan to invest $750 million in a new device fill finish facility in Hillsboro, Oregon, has put Roche Holding (SWX:ROP) back in focus for investors watching its U.S. manufacturing footprint. See our latest analysis for Roche Holding. Roche Holding’s recent manufacturing announcements have landed against a strong run in the stock, with a 13.0% 1 month share price return and a 15.4% year to date share price return, while the 1 year total shareholder return of 48.0% points to building...
21 ago 2026
Roche Holding stock has delivered a 58.5% return over the past three years, yet the current valuation checks give a more mixed read on how much upside may be left in the price. Roche Holding's 58.5% three year return highlights that shareholders have already seen solid gains, so fresh buyers need to think carefully about what is now priced in. Large ongoing investments in U.S. manufacturing facilities and collaborations in diagnostics can support expectations for future cash flows, while the...
20 ago 2026
Roper Technologies has underperformed the market, while analysts remain moderately optimistic on its future prospects.
Roper repurchased over 8% of its shares for $3.2B during a software sector selloff, capitalizing on depressed valuations. Read more on ROP stock here.
19 ago 2026
Illumia, an award-winning leader in innovative higher education, healthcare, senior living, and corporate technology, today announced that participating colleges and universities can now accept tuition and fee payments
18 ago 2026
RBC Capital analyst Deane Dray reiterates Roper Technologies (NASDAQ:ROP) with a Sector Perform and maintains $417 price target.
17 ago 2026
ROPER TECHNOLOGIES (ROP) shows a strong technical setup with a 7/10 rating and bull flag pattern, offering a defined breakout entry above $408.09.
Roper Technologies (NASDAQ:ROP) is pursuing a strategy centered on long-term free-cash-flow-per-share growth, portfolio collaboration and acquisitions of vertical-market software businesses, while increasingly deploying artificial intelligence across its operations and products, Chief Financial Offi
14 ago 2026
Roper's Application Software segment drives growth as SaaS adoption, GenAI innovation and recurring revenues support strong momentum.
11 ago 2026
Roper Technologies, Inc. (ROP) Oppenheimer 29th Annual Technology, Internet & Communications Conference August 11, 2026 9:55 AM EDTCompany...
10 ago 2026
Software stocks are staging a comeback in the second half of the year, according to Jefferies analysts, who pointed to strong results from ServiceNow Inc (NYSE:NOW, XETRA:4S0), SAP, Roper Technologies, Atlassian (NASDAQ:TEAM) and Cloudflare as evidence the sector is shaking off fears of...
6 ago 2026
Argus Research analyst John Eade upgrades Roper Technologies (NASDAQ:ROP) from Hold to Buy and announces $450 price target.
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
5 ago 2026
Roche Holding (SWX:ROP) has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant. The partnership focuses on a Phase 1b trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The agreement centers on a breast cancer segment with significant unmet medical need. Roche Holding, traded as SWX:ROP, is adding this collaboration to an oncology portfolio that already plays a central role in the company’s identity. The stock...
